WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Firm News

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million. 

Stuart Falber led the WilmerHale team representing Tetraphase in this transaction, with a team that included Chris Barnstable-Brown, Emily Gainor and Tim Kulis

Visit www.tetraphase.com for more information. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.